A5027946039- Esophageal Cancer Research and Treatment
- Esophageal and GI Pathology
- Ovarian cancer diagnosis and treatment
- PARP inhibition in cancer therapy
- Occupational and environmental lung diseases
- Gastric Cancer Management and Outcomes
- Pleural and Pulmonary Diseases
- Intraperitoneal and Appendiceal Malignancies
- Colorectal and Anal Carcinomas
- Tracheal and airway disorders
- Neutropenia and Cancer Infections
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Renal cell carcinoma treatment
- Lung Cancer Research Studies
- Metastasis and carcinoma case studies
- Colorectal Cancer Surgical Treatments
- Angiogenesis and VEGF in Cancer
- Cancer Research and Treatments
- Diagnosis and treatment of tuberculosis
- Colorectal Cancer Screening and Detection
- Endometrial and Cervical Cancer Treatments
- Cervical Cancer and HPV Research
- Dysphagia Assessment and Management
Cardiff University
2020-2024
BackgroundPatients with advanced oesophageal cancer have a median survival of 3–6 months, and most require intervention for dysphagia. Self-expanding metal stent (SEMS) insertion is the typical form palliation in these patients, but dysphagia deterioration re-intervention are common. This study examined efficacy adjuvant external beam radiotherapy (EBRT) compared usual care alone preventing reducing service use after SEMS insertion.MethodsThis was multicentre, open-label, phase 3 randomised...
Impaired double strand DNA repair by homologous deficiency (HRD) leads to sensitivity poly ADP ribose polymerase (PARP) inhibition. Poly-ADP inhibitors target HRD induce synthetic lethality and are used routinely in the treatment of BRCA1 mutated ovarian cancer platinum-sensitive maintenance setting. A subset non-small cell lung cancers (NSCLCs) harbour impaired break repair. We therefore hypothesised that patients with metastatic exhibiting partial responses platinum doublet-based...
8507 Background: All patients with malignant pleural mesothelioma (MPM) eventually relapse following standard chemotherapy. However, there is no treatment option in this setting. Vinorelbine, exhibits useful clinical activity but has not been formally evaluated a randomised trial, despite its widespread off-label use worldwide. BRCA1 regulates spindle assembly checkpoint MPM and predicts vinorelbine sensitivity preclinical models [1,2], suggesting that negative may be chemoresistant....
BackgroundCurrently, there is no US Food and Drug Administration approved therapy for patients with pleural mesothelioma who have relapsed following platinum-doublet based chemotherapy. Vinorelbine has demonstrated useful clinical activity in mesothelioma, however its efficacy not been formally evaluated a randomised setting. BRCA1 expression required vinorelbine induced apoptosis preclinical models. Loss of may therefore correlate resistance.MethodsIn this randomised, phase 2 trial, were...
e21649 Background: Impaired DNA damage response (DDR) is a common feature of cancer, however therapeutic exploitation has been limited to cancers harbouring somatic inactivation BRCA1/2 which causes homologous recombination deficiency (HRD). We hypothesized that patients (pts) with metastatic non-small cell lung cancer responding platinum doublet based chemotherapy, might enrich for impaired DDR encompassing HRD, rendering these tumours more sensitive inhibition poly-ADP ribose polymerase...
4569 Background: Most patients with oesophageal cancer (OC) present incurable disease; 80% of new cases, and deaths, occur in low middle income nations. Median survival for advanced disease is 3-5 months, a majority requiring intervention dysphagia. Insertion self expanding metal stents the commonest way palliating, but dysphagia may recur within three months owing to tumour progression. Evidence reviews have called trials combination treatment OC The ROCS study (funding - UK NIHR programme)...
Background Most patients with oesophageal cancer present incurable disease. For those advanced disease, the mean survival is 3–5 months. Treatment emphasis therefore on effective palliation, majority of requiring intervention for dysphagia. Insertion a self-expanding metal stent provides rapid relief but dysphagia may recur within 3 months owing to tumour progression. Evidence reviews have called trials interventions combined stenting better maintain ability swallow. Objectives The...
TPS3630 Background: SCC of anus (SCCA) are considered rare tumours, but the incidence is increasing. Only 65% patients with later stage T3/T4 +/-N1 SCCA remain disease free at 3 years (Gunderson 2013, James 2013). The cytotoxicity IMCRT enhances tumour antigen presentation and promotes cytokine release as well enhancing MHC (Demaria 2004, Reits 2006). Immune therapy, against PD-1, have been approved for arising from other primary sites eg. head neck, lung cancer. addition such checkpoint...
<h3>Introduction/Background</h3> There is an unmet need to develop effective regimens for the treatment of advanced or recurrent endometrial cancer and a strong biological rationale investigate anti-angiogenic agents PARP inhibitors in this disease. <h3>Methodology</h3> Patients with advanced/recurrent after one prior line platinum-based chemotherapy ECOG Performance status 0–1 were randomised 1:1:1 weekly paclitaxel (80mg/m2 on days 1, 8 15 28-day cycle 6 cycles) without (PaW) cediranib...
Cytotoxic chemotherapy for ovarian cancer can be augmented by co-administration of vascular endothelial growth factor inhibitors but these are contraindicated in patients with bowel obstruction due to the risk gastrointestinal perforation. We evaluated safety and feasibility paclitaxel plus cediranib treat platinum-resistant at malignant obstruction. A phase II trial included eligible between March 2018 February 2021, identified clinical symptoms radiographic factors Cediranib (20 mg/day)...
Anti-angiogenic, VEGF inhibitors (VEGFi) increase progression-free survival (PFS) and, in some cases, overall many solid tumours. However, their use has been compromised by a lack of informative biomarkers. We have shown that plasma Tie2 is the first tumour vascular response biomarker for VEGFi ovarian, colorectal and gall bladder cancer: If concentrations do not change after 9 weeks treatment with VEGFi, patient does benefit, whereas confirmed reduction at least 10% defines hazard ratio...
<h3>Introduction/Background</h3> Systemic treatment of platinum-resistant advanced ovarian cancers (PROC) utilises cytotoxic chemotherapy and vascular endothelial growth factor receptor (VEGFR) inhibitors. However, patients at risk for malignant bowel obstruction (MBO) are excluded from this efficacious combination due to perforation. <h3>Methodology</h3> We conducted a Simon's two-stage trial combining oral VEGFR inhibitor cediranib (20 mg/day) with weekly paclitaxel (70 mg/m<sup>2</sup>),...